Enhanced therapeutic effect of PEDF-loaded mesenchymal stem cell-derived small extracellular vesicles against oxygen-induced retinopathy through increased stability and penetrability of PEDF.
Mesenchymal stem cells
Oxygen-induced retinopathy mouse model
Pigment epithelium-derived factor
Small extracellular vesicles
Journal
Journal of nanobiotechnology
ISSN: 1477-3155
Titre abrégé: J Nanobiotechnology
Pays: England
ID NLM: 101152208
Informations de publication
Date de publication:
08 Sep 2023
08 Sep 2023
Historique:
received:
24
05
2023
accepted:
16
08
2023
medline:
11
9
2023
pubmed:
9
9
2023
entrez:
8
9
2023
Statut:
epublish
Résumé
Several common retinal diseases that cause blindness are characterised by pathological neovascularisation accompanied by inflammation and neurodegeneration, including retinopathy of prematurity (ROP), diabetic retinopathy (DR), age-related macular degeneration (AMD), and retinal vein occlusion (RVO). The current treatment strategies for these diseases have limited benefits. Thus, safer and more effective alternative approaches are required. In this study, we loaded small extracellular vesicles (sEVs) derived from mesenchymal stem cell (MSC) with pigment epithelium-derived factor (PEDF), and tested the therapeutic effect of PEDF-loaded sEVs (PEDF-sEVs) using an oxygen induced retinopathy (OIR) mouse model, aiming to establish a new therapy strategy for the treatment of retinal pathological angiogenesis. We formulated PEDF-loaded sEVs (PEDF-sEVs) containing high concentrations of PEDF and evaluated their effects through in vivo and in vitro experiments. In OIR mice, PEDF-sEVs showed significantly better effects on retinal avascular areas, inflammation, and neuronal degeneration compared with the anti-vascular endothelial growth factor (VEGF) drug, which may indicate a possible advantage of PEDF-sEVs over anti-VEGF drugs in the treatment of pathological neovascularisation. In vitro, PEDF-sEVs greatly inhibited endothelial cell (EC) proliferation, migration, and tube formation by suppressing the VEGF-induced phosphorylation of extracellular signal-regulated kinase (ERK) and AKT (also known as Protein Kinase B). All experiments and analyses were performed in triplicate. PEDF-sEVs were more effective than PEDF or sEVs alone, both in vitro and in vivo. Furthermore, to determine the distribution of PEDF-sEVs, we used DiD-labelled sEVs and FITC-labelled PEDF to track the sEVs and PEDF, respectively. We found that PEDF-sEVs effectively reduced the degradation of PEDF. Loading PEDF on sEVs effectively enhanced the anti-angiogenic, anti-inflammatory, and neuroprotective effects of PEDF by increasing the stability and penetrability. These results suggest a potential role for PEDF-sEVs in retinal pathological neovascularisation.
Sections du résumé
BACKGROUND
BACKGROUND
Several common retinal diseases that cause blindness are characterised by pathological neovascularisation accompanied by inflammation and neurodegeneration, including retinopathy of prematurity (ROP), diabetic retinopathy (DR), age-related macular degeneration (AMD), and retinal vein occlusion (RVO). The current treatment strategies for these diseases have limited benefits. Thus, safer and more effective alternative approaches are required. In this study, we loaded small extracellular vesicles (sEVs) derived from mesenchymal stem cell (MSC) with pigment epithelium-derived factor (PEDF), and tested the therapeutic effect of PEDF-loaded sEVs (PEDF-sEVs) using an oxygen induced retinopathy (OIR) mouse model, aiming to establish a new therapy strategy for the treatment of retinal pathological angiogenesis.
RESULTS
RESULTS
We formulated PEDF-loaded sEVs (PEDF-sEVs) containing high concentrations of PEDF and evaluated their effects through in vivo and in vitro experiments. In OIR mice, PEDF-sEVs showed significantly better effects on retinal avascular areas, inflammation, and neuronal degeneration compared with the anti-vascular endothelial growth factor (VEGF) drug, which may indicate a possible advantage of PEDF-sEVs over anti-VEGF drugs in the treatment of pathological neovascularisation. In vitro, PEDF-sEVs greatly inhibited endothelial cell (EC) proliferation, migration, and tube formation by suppressing the VEGF-induced phosphorylation of extracellular signal-regulated kinase (ERK) and AKT (also known as Protein Kinase B). All experiments and analyses were performed in triplicate. PEDF-sEVs were more effective than PEDF or sEVs alone, both in vitro and in vivo. Furthermore, to determine the distribution of PEDF-sEVs, we used DiD-labelled sEVs and FITC-labelled PEDF to track the sEVs and PEDF, respectively. We found that PEDF-sEVs effectively reduced the degradation of PEDF.
CONCLUSIONS
CONCLUSIONS
Loading PEDF on sEVs effectively enhanced the anti-angiogenic, anti-inflammatory, and neuroprotective effects of PEDF by increasing the stability and penetrability. These results suggest a potential role for PEDF-sEVs in retinal pathological neovascularisation.
Identifiants
pubmed: 37684667
doi: 10.1186/s12951-023-02066-z
pii: 10.1186/s12951-023-02066-z
pmc: PMC10492320
doi:
Substances chimiques
pigment epithelium-derived factor
0
Oxygen
S88TT14065
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
327Subventions
Organisme : Tianjin Research Innovation Project for Postgraduate Students
ID : 2021YJSS148
Organisme : National Outstanding Youth Science Fund Project of National Natural Science Foundation of China
ID : 81800880
Organisme : National Natural Science Foundation of China
ID : 82171042
Organisme : National Natural Science Foundation of China
ID : 81870675
Organisme : Key Project of Internet Cross-Border Integration Innovation and Technology of Tianjin
ID : 18ZXRHSY00210
Organisme : Tianjin Key Medical Discipline (Specialty) Construction Project
ID : TJYXZDXK-037A
Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Int J Nanomedicine. 2008;3(2):133-49
pubmed: 18686775
Clin Sci (Lond). 2017 Jul 5;131(15):1763-1780
pubmed: 28679845
Eye (Lond). 2021 Oct;35(10):2812-2819
pubmed: 33257803
Sci Rep. 2017 Jun 28;7(1):4323
pubmed: 28659587
Invest Ophthalmol Vis Sci. 1989 Aug;30(8):1700-7
pubmed: 2668219
Invest Ophthalmol Vis Sci. 2013 Mar 21;54(3):2020-6
pubmed: 23449716
Exp Eye Res. 2020 Feb;191:107899
pubmed: 31866431
Mol Ther Nucleic Acids. 2019 Jun 7;16:778-790
pubmed: 31163320
Med Clin North Am. 2021 May;105(3):473-491
pubmed: 33926642
Am J Pathol. 2013 Apr;182(4):1379-90
pubmed: 23416159
Biomed Res Int. 2019 May 21;2019:2595801
pubmed: 31240207
J Biol Chem. 1993 Apr 25;268(12):8949-57
pubmed: 8473338
Lancet. 2010 Jul 10;376(9735):124-36
pubmed: 20580421
Br J Ophthalmol. 2007 Jul;91(7):885-7
pubmed: 17301120
Expert Opin Drug Discov. 2018 Apr;13(4):359-377
pubmed: 29382242
J Control Release. 2015 Jun 10;207:18-30
pubmed: 25836593
Sci Rep. 2016 Sep 30;6:34562
pubmed: 27686625
Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10242-7
pubmed: 10963684
Stem Cell Res Ther. 2022 Mar 7;13(1):100
pubmed: 35255957
Stem Cells Transl Med. 2019 Sep;8(9):880-886
pubmed: 31045328
Front Immunol. 2022 Mar 29;13:864956
pubmed: 35422798
Nat Protoc. 2009;4(11):1565-73
pubmed: 19816419
Invest Ophthalmol Vis Sci. 2014 Mar 28;55(3):1884-92
pubmed: 24550366
Mol Pharm. 2019 Jan 7;16(1):24-40
pubmed: 30513203
Proc Natl Acad Sci U S A. 2020 Nov 10;117(45):28297-28306
pubmed: 33106407
Horm Metab Res. 2003 Jun;35(6):382-6
pubmed: 12920663
Hum Gene Ther. 2001 Nov 1;12(16):2029-32
pubmed: 11727737
Diabetologia. 2003 Mar;46(3):394-400
pubmed: 12687338
Biochim Biophys Acta. 2014 Aug;1846(1):75-87
pubmed: 24747178
Protein Cell. 2019 Apr;10(4):295-299
pubmed: 29616487
Int J Mol Sci. 2018 Jan 01;19(1):
pubmed: 29301251
Cancer Lett. 2020 Aug 28;486:18-28
pubmed: 32439419
Theranostics. 2019 Feb 28;9(6):1714-1727
pubmed: 31037133
Exp Eye Res. 2022 Sep;222:109171
pubmed: 35809620
Am J Physiol Cell Physiol. 2017 Oct 1;313(4):C405-C420
pubmed: 28747334
Invest Ophthalmol Vis Sci. 2014 May 13;55(7):4568-76
pubmed: 24825105
J Ophthalmic Vis Res. 2019 Jul 18;14(3):336-366
pubmed: 31660113
Int J Mol Sci. 2014 Mar 07;15(3):4142-57
pubmed: 24608926
Diabetes. 2020 May;69(5):981-999
pubmed: 32139595
Nanomedicine. 2016 Apr;12(3):655-664
pubmed: 26586551
Am J Pathol. 2007 Jul;171(1):53-67
pubmed: 17591953
J Clin Med. 2021 Oct 12;10(20):
pubmed: 34682788
J Cell Physiol. 1995 Jan;162(1):110-8
pubmed: 7814443
Invest Ophthalmol Vis Sci. 2014 May 22;55(7):4165-74
pubmed: 24854853
Clin Sci (Lond). 2015 Jun;128(11):805-23
pubmed: 25881671
Nat Nanotechnol. 2021 Jul;16(7):748-759
pubmed: 34211166
Prog Retin Eye Res. 2021 Nov;85:100964
pubmed: 33713810
Front Med (Lausanne). 2022 Jun 15;9:910600
pubmed: 35783660
Exp Eye Res. 1991 Sep;53(3):411-4
pubmed: 1936177
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
Diabetes. 2001 Dec;50(12):2641-5
pubmed: 11723044
Life Sci. 2021 Jun 15;275:119351
pubmed: 33737084
Curr Eye Res. 2018 Sep;43(9):1190-1198
pubmed: 29857790
J Mol Med (Berl). 2022 Jun;100(6):817-828
pubmed: 35394143